Skip to main content
. 2020 Dec 14;13:175. doi: 10.1186/s13045-020-01011-z

Fig. 1.

Fig. 1

Novel agents and strategies targeting DLBCL cell surface antigens. mAb monoclonal antibody, ADC antibody–drug conjugate, BiTE bispecific T cell engager, CAR chimeric antigen receptor, NK natural killer, PD-1 programmed cell death protein 1